Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Congress 2022 | The role of BMT & clinical trials in patients with PV with multiple treatment-limiting toxicities

Joseph Scandura • 31 Oct 2022
MPN Congress 2022
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Joseph Scandura, MD, PhD, Weill Cornell Medicine and the New York Presbyterian Hospital, New York City, NY, highlights alternative treatment options available for patients with polycythemia vera (PV) that are experiencing multiple treatment-limiting toxicities, including clinical trials and bone marrow transplant (BMT). This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joseph Scandura

Are megakaryocytes the root of MPN evils?
Joseph Scandura • 24 Nov 2022
3:50
Changing clinical trial endpoints in MPNs & the link between hematopoietic fitness and outcomes
Joseph Scandura • 31 Oct 2022
1:47
The central role of megakaryocytes in MPN pathophysiology
Joseph Scandura • 31 Oct 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals